Science

Teva presents latest data on AJOVY® ▼ (fremanezumab) at EHF Congress

Teva Pharmaceutical Europe B.V. has presented results from a pooled analysis of three randomized, double-blind, placebo-controlled Phase 3 studies assessing AJOVY® ▼ (fremanezumab), indicated for the preventative treatment of migraine in adults, which demonstrate clinically significant reductions in headache and migraine-related disability in the majority of patients studied.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,